About Molecular Cancer

What is Molecular Cancer?

Molecular Cancer is an Open Access, peer-reviewed online journal interested in original research and commentary in all areas of cancer and related biomedical science.

Molecular Cancer promotes the exchange of ideas, concepts and findings in any area of cancer and related biomedical science. Molecular Cancer is interested in articles from basic, translational and clinical research, opening new avenues for the understanding, prevention, diagnosis and treatment of cancer. Molecular Cancer will consider articles from any area of cancer-related biomedical research, including, but not limited to: angiogenesis; animal models; metastasis; cancer antigens and the immune response to them; cellular signalling and molecular biology; epidemiology; genetic and molecular profiling of cancer; prevention, diagnosis and therapy of cancer; and vaccine- and antibody-based cancer therapies.

Molecular Cancer, a forum for exciting findings in the field of cancer-related research, is an Open Access journal, providing an unparalleled opportunity to present information to specialists and the public. The online appearance of Molecular Cancer allows the immediate publication of accepted articles and the presentation of large amounts of data and supplemental information.

Translations

The open access journal Archivos de Medicina offers authors whose papers have been accepted for publication in Molecular Cancer the option of publishing a Spanish translation of their article. Further details can be found here.

Content overview

Molecular Cancer considers the following types of articles:

• Research: comprehensive reports of data from original research, that reveal novel concepts of general importance and interest to the scientific community, with conclusions that deliver a substantial advance in the understanding of an important problem. The work should not only be of exceptional significance within its field but also of interest to researchers outside the immediate area. The journal also encourages 'Advanced Clinical Investigations', which are research articles of the highest quality pertaining to the molecular, cellular or physiological basis of cancer and cancer related diseases, epigenetics, animal models, cancer therapy, plus epidemiology and prevention.
• Short Communications: preliminary results of exceptional interest that are particularly topical and relevant, and for which fast publication is essential.
• Hypotheses: ideas or critics of ideas with discussion that will deliver a substantial advance in the understanding of an important problem.
• Commentaries: describe new developments of interdisciplinary significance, and highlight unresolved questions and future directions.
• Reviews: invited articles describing new developments of interdisciplinary significance and highlighting unresolved questions and future directions; it provides a critical but balanced view of the field. Reviews should focus on one topical aspect of a field rather than providing a comprehensive literature survey; they can be controversial, but should indicate opposing viewpoints.
• Book Reviews: are rare articles invited by the Editorial Board. These articles are short summaries of the strengths and weaknesses of a book, and should evaluate the overall usefulness of the book to the intended audience.

Peer review policies

• The editorial board screens submitted manuscripts. If the manuscript falls within the scope of Molecular Cancer, it will be assigned to at least two reviewers, whose comments are sent to the authors without delay.
• Peer reviewers will have four possible options for each manuscript:
  • accept without revision
  • accept after revision without expecting to check those revisions
  • neither accept nor reject until author(s) make revisions
  • reject because the work presented is scientifically unsound.
• Molecular Cancer allows two revisions of an article.

Edited by Alan Storey, Molecular Cancer is supported by an expert Editorial Board.

Publishing in Molecular Cancer

All articles will be listed in PubMed immediately upon acceptance (after peer review), and will be covered by PubMed Central, MEDLINE, Thomson Reuters (ISI), CAS, Biosis, Embase and Current Contents.

Articles in Molecular Cancer should be cited in the same way as articles in a traditional journal. However, because articles in this journal are not printed, they do not have page numbers. Instead, they have a unique article number.

The following citation:

Mol Cancer 2004, 2:1

refers to article 1 from volume 2 of the journal.

As an online journal, Molecular Cancer does not have issue numbers. Each volume corresponds to a calendar year.

To keep up to date with the latest articles from Molecular Cancer, why not register to receive alerts? Registration also enables you to customise your subject areas of interest, store your searches, and submit your manuscripts.

Submission of manuscripts

Manuscripts should be submitted electronically to Molecular Cancer using the online submission system. Full details of how to submit a manuscript are given in the instructions for authors.

General journal policies

Molecular Cancer is published  by BioMed Central, an independent publisher committed to ensuring peer-reviewed biomedical research is Open Access. That means it is freely and universally accessible online, it is archived in at least one internationally recognised free access repository, and its authors retain copyright, allowing anyone to reproduce or disseminate articles, according to the BioMed Central copyright and licence agreement. Molecular Cancer however, has taken this further by making all its content Open Access.

Molecular Cancer's articles are archived in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and also at INIST in France and in e-Depot, the National Library of the Netherlands' digital archive of all electronic publications. The journal is also participating in the British Library's e-journals pilot project, and plans to deposit copies of all articles with the British Library.

BioMed Central is working closely with the Thomson Reuters (ISI) to ensure that citation analysis of articles published in Molecular Cancer will be available.

Molecular Cancer is able to deliver summaries of frequently updated content via Really Simple Syndication (RSS) feeds. These are accessible via the orange "XML" button at the top of the list of recent articles or the list of most accessed articles. For more information about RSS feeds see our publisher's website.

For further information about general policies please see the instructions for authors.